covid-19 患者血浆组织因子途径抑制物（tfpi）水平升高，但其在凝血中的作用不明。研究人员利用 covid-19 临床试验血样，测定 tfpi 和凝血酶生成等。结果发现 tfpi 延迟凝血酶生成和凝块形成，但与血栓等临床结局无关，为理解 covid-19 凝血机制提供依据。

Marstacimab（马塔西单抗）是一种靶向TFPI的人源IgG1单克隆抗体，通过靶向TFPI的Kunitz-2结构域，重新建立出血和凝血之间的平衡；即使患者体内存在抑制 ...

为评估 TFPI 对慢性肾病（CKD）和糖尿病患者动脉粥样硬化血栓事件（ATE）的预测能力，研究发现 TFPI 在 CKD 患者中可预测 ATE，意义重大。 在心血管疾病（CVD）的防治领域，寻找精准预测心血管风险的生物标志物一直是研究热点 ...

On June 26, Pfizer announced positive topline results from its Phase 3 BASIS study evaluating HYMPAVZI (marstacimab) for ...

Pfizer PFE announced that the phase III BASIS study evaluating its anti-TFPI inhibitor Hympavzi (marstacimab) for treating patients with hemophilia A or B with inhibitors met its primary endpoint as ...

Alhemo is an anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody that, if approved by the European Commission, will offer the first once-daily subcutaneous prophylactic treatment to people ...

Tissue factor pathway inhibitor-2 reduces interstitial collagenase degradation of triple-helical collagen and may be of use in the treatment of atherosclerosis. Login. Subscribe. News; Magazines. An ...

Hympavzi targets the Kunitz-2 domain of tissue factor pathway inhibitor (TFPI), a natural anticoagulation protein. In developing the treatment, Pfizer trailed Novo Nordisk’s investigational TFPI ...

FDA today approved marstacimab, an anti-tissue factor pathway inhibitor (anti-TFPI) to prevent or reduce bleeding episodes in patients with hemophilia A and B. Marstacimab, to be sold as Hympavzi ...

Alhemo ® is an anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody that, if approved by the European Commission, will offer the first once-daily subcutaneous prophylactic treatment to ...